- Home
- IBRX
IBRX
ImmunityBio Inc.
as 12-17-2024 4:00pm EST
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.4B | IPO Year: | N/A |
| Target Price: | $17.38 | AVG Volume (30 days): | 5.6M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.81 - $10.53 | Next Earning Date: | 11-12-2024 |
| Revenue: | $7,332,000 | Revenue Growth: | 1218.71% |
| Revenue Growth (this year): | 2572.99% | Revenue Growth (next year): | 747.59% |
Latest ImmunityBio Inc. News
IBRX Breaking Stock News: Dive into IBRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
Business Wire
7 days ago
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
Business Wire
8 days ago
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
Insider Monkey
25 days ago
Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds
PR Newswire
a month ago
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
Simply Wall St.
a month ago
High Growth Tech Stocks To Watch In November 2024
Business Wire
a month ago
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
Business Wire
a month ago
ImmunityBio Reports Third-Quarter 2024 Financial Results
Compare IBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IBRX ImmunityBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.